Skip to main content
OpenTrials
Completed

NCT Number: NCT03770442

Muscle Wasting in the Critically Ill

Muscle wasting is a common consequence of critical illness, and has a profound impact upon the rehabilitation of those who survive admission to critical to care. The investigators intend to assess if the application of 10 sessions over two weeks of passive cycling with electrical stimulation to the lower limbs and abdomen can prevent muscle loss, or at least cause less muscle loss, compared to patients who receive standard daily sessions of physiotherapy. This will be done by comparing the changes in muscle size on ultrasound between the two groups, comparing functional measures at a 3 month follow up, and by performing translational research using tissue samples taken during the study.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–90 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Intensive Care Unit, Royal Liverpool University Hospital

Liverpool, L7 8XP, United Kingdom

About this study

Patients are mechanically ventilated and sedated with a diagnosis of sepsis (from any source) will be eligible for this study. Provided they meet the inclusion criteria, they will be randomised within 48 hours of admission, to either ten 30 minute sessions of passive cycling with functional electrical stimulation (FES) to the thighs, hamstrings, calves and abdomen over a 14 day period, or to a control group of routine physiotherapy. The trial group will also receive this physiotherapy.

On admission to the study, all patients will receive on day 1:

Ultrasound measurements of:

Rectus femoris cross-sectional area Thickness of rectus femoris and vastus intermedius Thickness, pennation angle and derived fascicle length of vastus lateralis and medial head of gastrocnemius Thickness of rectus abdominis. Thickness of diaphragm

A blood sample taken from an arterial line A urine sample taken from a urinary catheter A muscle biopsy taken from the right vastus lateralis

They will then receive ten 30 minute sessions of passive cycling with functional electrical stimulation over 14 days, or a control group will receive routine physiotherapy during this period.

Repeat ultrasounds will be taken at days 3, 5, 7, 10 and 14. Repeat blood and urine sampling at days 5, 10 and 14. Repeat muscle biopsy at day 14.

All cycling, ultrasounds and tissue sampling will end on day 14 regardless of the ventilator status of the patient.

In patients who survive to be discharged from critical care, they will be followed up at 3 months for:

Repeat ultrasound scan of all muscles listed Six minute walk test Hand grip and lower limb dynamometry, Balance testing (by standing upright on a pressure plate for 20 seconds) Psychological assessment using the 36 item Short Form (SF-36) questionnaire

Tissue sampling will be stored in the University of Liverpool for analysis of biomarkers of muscle damage and loss between the two groups.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients will be recruited in the Intensive Care Unit of the Royal Liverpool University Hospital. All patients will be over 18, and have a critical illness that requires mechanical ventilation with an initial period of sedation. This study will focus on patients with a definite or suspected case of sepsis from any source.

Sepsis has been recently redefined as: "Life threatening organ-dysfunction caused by dysregulated host response to infection" whilst septic shock has become a subset of sepsis, defined as: "circulatory and cellular/metabolic dysfunction associated with a higher risk of mortality(44).

For the purposes of this study, a patient will be regarded as septic if they have evidence of infection-related organ failure (e.g. sepsis-associated coagulopathy, altered mental state, cardiovascular dysfunction, acute kidney injury, and altered liver function) and require invasive mechanical ventilation with either definite or suspected evidence of infection. This is to allow prompt treatment with FES rather than waiting for a positive microbiological result to be obtained.

Within the definition of sepsis "from any source" a list of following is illustrative but not exhaustive:

  • Urogenital sepsis (including urosepsis, pyelonephritis, endometritis and chorioamnionitis)
  • Pneumonia (including community acquired, hospital acquired, and aspiration pneumonia. Ventilator associated pneumonia would be excluded.)
  • Neurological infections such as encephalitis and meningitis.
  • Cellulitis, osteomyelitis and infections of soft tissue NOT affecting the lower limb.
  • Surgical infections, including post-operative laparotomy with evidence of peritoneal soiling, and evidence of infection prior to the operation, in patients who require 2 or more organ system support after the operation.
  • Intra-abdominal sepsis, including biliary sepsis, hepatitis, and acute pancreatitis. In the case of acute pancreatitis, evidence of infection is required to fulfil the criteria. Acute pancreatitis with sterile tissue/fluid samples would not be suitable.

Exclusion criteria

  • Patients under 18
  • Patients who decline consent
  • Pregnancy
  • Neuromuscular disease
  • Rhabdomyolysis
  • Lower limb trauma
  • Patients unlikely to survive to 96 hours post admission
  • Consent unobtainable within 48 hours of admission
  • Morbid obesity (BMI>40).
  • Presence of a pacemaker or Implantable Cardiac Defibrillator (ICD).
  • Unlikely to be mechanically ventilated for more than 48 hours.

Treatment and study plan

Cycling with FES

Device

As described already

Other names: RT-300 Supine, Restorative Therapies

Routine physiotherapy

Other

As described already

Primary outcomes

  1. Ultrasound assessment of rectus femoris - Change in cross sectional area (cm2)

    Time frame: Ultrasounds taken on day 1, 3, 5, 7, 10 and 14, and at 3 month follow up.

    Measurement of cross-sectional area of rectus femoris (cm2)

  2. Ultrasound assessment of rectus femoris - Change in muscle layer thickness (cm)

    Time frame: Ultrasounds taken on day 1, 3, 5, 7, 10 and 14, and at 3 month follow up.

    Measurement on muscle layer thickness of rectus femoris (cm)

  3. Ultrasound assessment of anterior thigh musculature - Change in muscle layer thickness (cm)

    Time frame: Ultrasounds taken on day 1, 3, 5, 7, 10 and 14, and at 3 month follow up.

    Measurement of combined muscle layer thickness of rectus femoris and vastus intermedius (cm)

  4. Ultrasound assessment of vastus lateralis - change in muscle layer thickness (cm)

    Time frame: Ultrasounds taken on day 1, 3, 5, 7, 10 and 14, and at 3 month follow up.

    Measurement of the thickness of the vastus lateralis between the superficial and deep aponeuroses (cm)

  5. Ultrasound assessment of vastus lateralis - change in fascicle pennation angle (degrees)

    Time frame: Ultrasounds taken on day 1, 3, 5, 7, 10 and 14, and at 3 month follow up.

    Measurement of the pennation angle of the muscle fascicles as they insert into the deep aponeuroses of the vastus lateralis muscle (degrees)

  6. Ultrasound assessment of vastus lateralis - change in fascicle length (cm)

    Time frame: Ultrasounds taken on day 1, 3, 5, 7, 10 and 14, and at 3 month follow up.

    This is a single measure, derived by trigonometry (the Sine of the pennation angle multiplied by the muscle thickness).

  7. Ultrasound assessment of the medial head of gastrocnemius - change in muscle thickness (cm)

    Time frame: Ultrasounds taken on day 1, 3, 5, 7, 10 and 14, and at 3 month follow up.

    Measurement of the thickness of the medial head of the gastrocnemius between the superficial and deep aponeuroses (cm)

  8. Ultrasound assessment of the medial head of gastrocnemius - change in fascicle pennation angle (degrees)

    Time frame: Ultrasounds taken on day 1, 3, 5, 7, 10 and 14, and at 3 month follow up.

    Measurement of the pennation angle of the muscle fascicles as they insert into the deep aponeuroses of the medial head of gastrocnemius (angles)

  9. Ultrasound assessment of the medial head of gastrocnemius - change in fascicle length (cm)

    Time frame: Ultrasounds taken on day 1, 3, 5, 7, 10 and 14, and at 3 month follow up.

    This is single measure which is mathematically derived by trigonometry using the known pennation angle (degrees) and thickness (cm): the Sine of the pennation angle multiplied by the muscle thickness.

  10. Ultrasound assessment of the rectus abdominis muscle - change in muscle layer thickness (cm)

    Time frame: Ultrasounds taken on day 1, 3, 5, 7, 10 and 14, and at 3 month follow up.

    Measurement of rectus abdominis muscle layer thickness - (cm)

  11. Diaphragm thickness assessment by ultrasound - change in end expiratory thickness (mm)

    Time frame: Ultrasounds taken on day 1, 3, 5, 7, 10 and 14, and at 3 month follow up.

    Assessment of thickness at end expiration (mm)

  12. Diaphragm thickness assessment by ultrasound - change in end inspiratory thickness (mm)

    Time frame: Ultrasounds taken on day 1, 3, 5, 7, 10 and 14, and at 3 month follow up.

    Assessment of thickness at end inspiration (mm)

  13. Diaphragm thickness assessment by ultrasound - change in thickening fraction (%)

    Time frame: Ultrasounds taken on day 1, 3, 5, 7, 10 and 14, and at 3 month follow up.

    Assessment of thickening fraction, derived mathematically from thicknesses at inspiration and expiration (%)

  14. Ultrasound assessment of change in diaphragmatic excursion (cm)

    Time frame: Ultrasounds taken on day 1, 3, 5, 7, 10 and 14, and at 3 month follow up.

    Assessment of maximal excursion of diaphragm, measured with M-mode ultrasonography (mm)

Secondary outcomes

  1. Measurement of change in blood biomarkers (microRNA analysis for markers of muscle loss, expressed as a percentage fold increase/decrease compared to baseline).

    Time frame: Samples taken on days 1, 5, 10 and 14

    Blood samples taken during the study period and analysed for markers of muscle loss/degradation

  2. Measurement of change in urinary biomarkers (microRNA analysis for markers of muscle loss, expressed as a percentage-fold increase/decrease compared to baseline).

    Time frame: Samples taken on days 1, 5, 10 and 14

    Blood and urine samples taken during the study period and analysed for markers of muscle loss/degradation

  3. Measurement of the number of biomarkers expressed from muscle biopsies (microRNA analysis for markers of muscle loss, expressed as the number and type of micro-RNAs expressed within the samples).

    Time frame: Samples taken on day 1 and 14

    Muscle biopsy samples taken during the study period and analysed for markers of muscle loss/degradation. Number and type of micro-RNAs to be noted).

  4. Measurement of muscle fibre cross sectional area from muscle biopsies (mm2)

    Time frame: Samples taken on day 1 and 14

    Histological staining and analysis of muscle fibre composition, expressed in square millimetres and as a percentage-fold increase/decrease compared to baseline).

  5. Follow up testing - Distance achieved in a 6 minute walk test, metres)

    Time frame: At 3 month follow up

    Distance achieved during a 6 minute shuttle walk of 20 metres length

  6. Follow up testing - Hand grip dynamometry (hand grip strength, Newtons)

    Time frame: At 3 month follow up

    Strength of hand grip in both hands

  7. Follow up - Lower limb strength assessment - Force generated at maximal contraction for knee extension (Newtons)

    Time frame: At 3 month follow up

    Strength of extension at the knee in both legs using a hand held dynamometry device (microFET 2 wireless device). Measured in Newtons.

  8. Follow up testing - Balance assessment - Comparison of changes in center of pressure on a pressure plate.

    Time frame: At 3 month follow up

    Comparison of changes in centre of pressure on a pressure plate. The centre of pressure is measured over 20 seconds with the participant standing still. Maximal variation in lateral and anterior-posterior sway is recorded by the pressure plate.

  9. Follow up testing - Psychological assessment - Comparison of total scores obtained from the SF-36 questionnaire (maximum score 100, minimum score zero).

    Time frame: At 3 month follow up

    Comparison of scores obtained from the SF-36 questionnaire between the two groups. A lower score indicates greater disability.

  10. Follow Up - Maximal Inspiratory Pressure monitoring in kilopascals (kPa)

    Time frame: At 3 month follow up

    Using the Power Breathe K2 device

  11. Incidence of delirium during the trial period - using the CAM-ICU tool.

    Time frame: Days 1-14

    Assessed by twice daily Cambridge Assessment Method for the ICU (CAM-ICU) assessments

  12. Incidence of renal replacement therapy during the trial period

    Time frame: Days 1-14

    Daily monitoring to see if patient has required renal replacement therapy (defined as either haemofiltration or haemodialysis).

  13. Total dose of noradrenaline given per day

    Time frame: Day 1-14

    Daily monitoring of doses of inotropic and vasopressor drugs

  14. Overall fluid balance (in mls) at the end of each study day

    Time frame: Day 1-14

    Daily noting of 24 hour fluid balance

  15. Total Insulin doses (in international units) required per day

    Time frame: Day 1-14

    Daily monitoring of exogenous insulin requirements

  16. Blood glucose concentration (mmol/L)

    Time frame: Day 1-14

    Daily monitoring of glucose levels

  17. Heart rate variability

    Time frame: Days 1 - 14 but only on the days where cycling takes place (ten sessions)

    Measured via a wireless skin patch

  18. Safety - number of times an endotracheal/tracheostomy tube is dislodged during the cycling sessions

    Time frame: Days 1 - 14 but only on the days where cycling takes place (ten sessions)

    Expressed as a simple count of how many times an airway device dislodges

  19. Safety - number of times an nasogastric tube is dislodged during the cycling sessions

    Time frame: Days 1 - 14 but only on the days where cycling takes place (ten sessions).

    Expressed as a simple count of how many times a nasogastric feed tube dislodges.

  20. Safety - number of times an a central or arterial line device is dislodged during the cycling sessions

    Time frame: Days 1 - 14 but only on the days where cycling takes place (ten sessions).

    Expressed as a simple count of how many times a central or arterial line dislodges.

Sponsors and collaborators

Lead sponsor

University of Liverpool

Other

Registry information

Official study title

Effect of Early Rehabilitation Using an Active/Passive Cycling Device on Muscle Wasting in the Critically Ill: A Randomised Controlled Study

Important dates

Study start
2019
Primary completion
2020
Study completion
2020
First posted
Dec 10, 2018
Registry last updated
Nov 4, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.